Abstract Purpose To predict the gamma passing rate (GPR) of the three-dimensional (3D) detector array-based volumetric modulated arc therapy (VMAT) quality assurance (QA) for prostate cancer using a convolutional neural network (CNN) with the 3D dose distribution. Methods One hundred thirty-five VMAT plans for prostate cancer were selected: 110 plans were used for training and validation, and 25 plans were used for testing. Verification plans were measured using a helical 3D diode array (ArcCHECK). The dose distribution on the detector element plane of these verification plans was used as input data for the CNN model. The measured GPR (mGPR) values were used as the training data. The CNN model comprises eighteen layers and predicted GPR (pGPR) values. The mGPR and pGPR values were compared, and a cumulative frequency histogram of the prediction error was created to clarify the prediction error tendency. Results The correlation coefficients of pGPR and mGPR were 0.67, 0.69, 0.66, and 0.73 for 3%/3-mm, 3%/2-mm, 2%/3-mm, and 2%/2-mm tolerances, respectively. The respective mean\(\pm\)standard deviations of pGPR\(-\)mGPR were \(-\)0.87\(\pm\)2.18%, \(-\)0.65\(\pm\)2.93%, \(-\)0.44\(\pm\)2.53%, and \(-\)0.71\(\pm\)3.33%. The probabilities of underestimate cases (pGPR < mGPR) were 72%, 60%, 68%, and 56% for each tolerance. Conclusions We developed a deep learning-based prediction model of the 3D detector array-based VMAT QA for prostate cancer, and evaluated the accuracy and tendency of prediction GPR. This model can provide a proactive estimation for the results of the patient-specific QA before the verification measurement.